MAP2K7 and colorectal carcinoma: The BEACON CRC trial highlights promising therapeutic avenues, as the combination of encorafenib (BRAF inhibitor), binimetinib (MEK inhibitor), and cetuximab (anti-EGFR antibody) has demonstrated a survival benefit (9.0 months) and a 26% response rate in advanced CRC, underscoring the efficacy of multi-targeted regimens in overcoming pathway reactivation [44,45].